Advertisement

Skene's Gland Malignancy: A Case Report and Systematic Review

Published:February 19, 2022DOI:https://doi.org/10.1016/j.urology.2022.02.004

      Abstract

      Objective

      To present a recent clinical case of Skene's gland carcinoma and review all published literature of Skene's gland malignancy with associated treatment and outcomes.

      Methods

      We review a new case of metastatic Skene's gland adenocarcinoma. We then performed a systematic search of PubMed and Ovid-Medline through December 2021 and retrieved English language articles for review. Peer-reviewed articles were deemed eligible if they included patients with Skene's gland malignancy. Reports were reviewed for pathologic accuracy, patient characteristics, clinical presentation, tumor pathology, treatment and outcome.

      Results

      We reviewed 211 articles and included 15 cases from 1974 to 2022. The median patient age was 71 years (range 46-88). The most common presentation was an asymptomatic periurethral or urethral lesion in five cases (33.3%), followed by hematuria or vaginal bleeding in three patients (20.0%). In eight cases, a prostate-specific antigen was measured and found to be elevated, range 0.8-60.8 ng/mL. Treatment approaches varied and included local excision in eight cases, radical surgical resection in two cases, radiation therapy in two cases, and adjunctive androgen deprivation therapy in one case. Pathology was consistent with adenocarcinoma resembling prostate in all cases. In all cases tested, prostate-specific antigen normalized after definitive therapy of any type. Median follow up was 11.5 months, and there were no cases of recurrence or mortality secondary to Skene's gland adenocarcinoma.

      Conclusion

      There are 15 published cases of a Skene's gland malignancy, all adenocarcinoma resembling prostate. Local excision is most often utilized for treatment, with androgen deprivation therapy emerging as a new treatment consideration.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Huffman JW.
        The detailed anatomy of the para-urethral ducts in the adult human female.
        Am J Obstet Gynecol. 1948; 55: 86-101https://doi.org/10.1016/0002-9378(48)90157-4
        • Tepper SL
        • Jagirdar J
        • Heath D
        • Geller SA.
        Homology between the female paraurethral (Skene's) glands and the prostate. Immunohistochemical demonstration.
        Arch Pathol Lab Med. 1984; 108: 423-425
        • Heller DS.
        Lesions of Skene glands and periurethral region: a review.
        J Low Genit Tract Dis. 2015; 19: 170-174https://doi.org/10.1097/LGT.0000000000000059
        • Kazakov DV
        • Stewart CJ
        • Kacerovska D
        • et al.
        Prostatic-type tissue in the lower female genital tract: a morphologic spectrum, including vaginal tubulosquamous polyp, adenomyomatous hyperplasia of paraurethral Skene glands (female prostate), and ectopic lesion in the vulva.
        Am J Surg Pathol. 2010; 34: 950-955https://doi.org/10.1097/PAS.0b013e3181e0f371
        • Dodson MK
        • Cliby WA
        • Keeney GL
        • Peterson MF
        • Podratz KC.
        Skene's gland adenocarcinoma with increased serum level of prostate-specific antigen.
        Gynecol Oncol. 1994; 55: 304-307https://doi.org/10.1006/gyno.1994.1294
        • Dodson MK
        • Cliby WA
        • Pettavel PP
        • Keeney GL
        • Podratz KC.
        Female urethral adenocarcinoma: evidence for more than one tissue of origin?.
        Gynecol Oncol. 1995; 59: 352-357https://doi.org/10.1006/gyno.1995.9963
        • McCluggage WG
        • Young RH.
        Tubulo-squamous polyp: a report of ten cases of a distinctive hitherto uncharacterized vaginal polyp.
        Am J Surg Pathol. 2007; 31: 1013-1019https://doi.org/10.1097/PAS.0b013e31802bdd72
        • Murphy DP
        • Pantuck AJ
        • Amenta PS
        • et al.
        Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin.
        J Urol. 1999; 161: 1881-1884https://doi.org/10.1016/s0022-5347(05)68833-7
        • Muto M
        • Inamura K
        • Ozawa N
        • et al.
        Skene's gland adenocarcinoma with intestinal differentiation: a case report and literature review.
        Pathol Int. 2017; 67: 575-579https://doi.org/10.1111/pin.12571
        • Sloboda J
        • Zaviacic M
        • Jakubovský J
        • Hammar E
        • Johnsen J.
        Metastasizing adenocarcinoma of the female prostate (Skene's paraurethral glands). Histological and immunohistochemical prostate markers studies and first ultrastructural observation.
        Pathol Res Pract. 1998; 194: 129-136https://doi.org/10.1016/S0344-0338(98)80080-0
        • Tregnago AC
        • Epstein JI.
        Skene's glands adenocarcinoma: a series of 4 cases.
        Am J Surg Pathol. 2018; 42: 1513-1521https://doi.org/10.1097/PAS.0000000000001108
        • Balshem H
        • Helfand M
        • Schünemann HJ
        • et al.
        GRADE guidelines: 3. Rating the quality of evidence.
        J Clin Epidemiol. 2011; 64: 401-406https://doi.org/10.1016/j.jclinepi.2010.07.015
        • Kaufman ME
        • Miller DT
        • Ullah A
        • et al.
        Skene's gland adenocarcinoma: borrowing from prostate cancer experience for the evaluation and management of a rare malignancy.
        Urology. 2020; https://doi.org/10.1016/j.urology.2020.05.032
        • Reis LO
        • Billis A
        • Ferreira FT
        • Ikari LY
        • Stellini RF
        • Ferreira U.
        Female urethral carcinoma: evidences to origin from Skene's glands.
        Urol Oncol. 2011; 29: 218-223https://doi.org/10.1016/j.urolonc.2009.03.019
        • Dell'Atti L
        • Galosi AB.
        Female urethra adenocarcinoma.
        Clin Genitourin Cancer. 2018; 16: e263-e267https://doi.org/10.1016/j.clgc.2017.10.006
        • Lenz J
        • Michal M
        • Hes O
        • Konečná P
        • Lenz D.
        First molecular genetic characterization of skene's gland adenocarcinoma.
        Int J Surg Pathol. 2021; 29: 447-453https://doi.org/10.1177/1066896920947808
        • Hollander MC
        • Blumenthal GM
        • Dennis PA.
        PTEN loss in the continuum of common cancers, rare syndromes and mouse models.
        Nat Rev Cancer. 2011; 11: 289-301https://doi.org/10.1038/nrc3037
        • Liu D
        • Augello MA
        • Grbesa I
        • et al.
        Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
        J Clin Invest. 2021; 131https://doi.org/10.1172/JCI147878
        • Wilkinson S
        • Ye H
        • Karzai F
        • et al.
        Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy.
        Eur Urol. 2021; 80: 746-757https://doi.org/10.1016/j.eururo.2021.03.009
        • Robinson D
        • Van Allen EM
        • Wu YM
        • et al.
        Integrative clinical genomics of advanced prostate cancer.
        Cell. 2015; 161: 1215-1228https://doi.org/10.1016/j.cell.2015.05.001
        • Jacob J
        • Necchi A
        • Grivas P
        • et al.
        Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.
        Urol Oncol. 2021; 39: 731.e1-731.e15https://doi.org/10.1016/j.urolonc.2020.12.021
        • Gakis G
        • Witjes JA
        • Compérat E
        • et al.
        EAU guidelines on primary urethral carcinoma.
        Eur Urol. 2013; 64: 823-830https://doi.org/10.1016/j.eururo.2013.03.044
        • Mohler JL
        • Antonarakis ES
        • Armstrong AJ
        • et al.
        Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2019; 17: 479-505https://doi.org/10.6004/jnccn.2019.0023
        • Korytko TP
        • Lowe GJ
        • Jimenez RE
        • Pohar KS
        • Martin DD.
        Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma.
        Urol Oncol. 2012; 30: 602-606https://doi.org/10.1016/j.urolonc.2010.06.015
        • Kyriazis G
        • Varughese A
        • Rodrigues G
        • Simms M.
        A rare case of skene's gland adenocarcinoma.
        Clin Genitourin Cancer. 2020; 18: e300-e302https://doi.org/10.1016/j.clgc.2019.11.022
        • Pongtippan A
        • Malpica A
        • Levenback C
        • Deavers MT
        • Silva EG.
        Skene's gland adenocarcinoma resembling prostatic adenocarcinoma.
        Int J Gynecol Pathol. 2004; 23: 71-74https://doi.org/10.1097/01.pgp.0000101144.79462.39
        • Tsutsumi S
        • Kawahara T
        • Hattori Y
        • et al.
        Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report.
        J Med Case Rep. 2018; 12: 32https://doi.org/10.1186/s13256-017-1558-y
        • Zaviacic M
        • Sidlo J
        • Borovský M.
        Prostate specific antigen and prostate specific acid phosphatase in adenocarcinoma of Skene's paraurethral glands and ducts.
        Virchows Arch A Pathol Anat Histopathol. 1993; 423: 503-505https://doi.org/10.1007/BF01606542
        • Svanholm H
        • Andersen OP
        • Røhl H.
        Tumour of female paraurethral duct. Immunohistochemical similarity with prostatic carcinoma.
        Virchows Arch A Pathol Anat Histopathol. 1987; 411: 395-398https://doi.org/10.1007/BF00713386